Bio-Connect

InVivoMAb anti-mouse OX40L (CD134L)

BE0033-1
Bio X Cell
ApplicationsNeutralisation/Blocking
Product group Antibodies
ReactivityMouse
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Bio X Cell
  • Product Name
    InVivoMAb anti-mouse OX40L (CD134L)
  • Delivery Days Customer
    7
  • Applications
    Neutralisation/Blocking
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    RM134L
  • Concentration
    4-11 mg/ml
  • Estimated Purity
    >95%
  • Host
    Rat
  • Isotype
    IgG2b
  • Reactivity
    Mouse
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352203

References

  • Welten SP, Redeker A, Franken KL, et al. The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansion. Elife. 2015,4. doi: 10.7554/eLife.07486
    Read this paper
  • Baeyens A, Saadoun D, Billiard F, et al. Effector T cells boost regulatory T cell expansion by IL-2, TNF, OX40, and plasmacytoid dendritic cells depending on the immune context. J Immunol. 2015,194(3):999-1010. doi: 10.4049/jimmunol.1400504
    Read this paper
  • Xin L, Jiang TT, Chaturvedi V, et al. Commensal microbes drive intestinal inflammation by IL-17-producing CD4+ T cells through ICOSL and OX40L costimulation in the absence of B7-1 and B7-2. Proc Natl Acad Sci U S A. 2014,111(29):10672-7. doi: 10.1073/pnas.1402336111
    Read this paper
  • Mahmud SA, Manlove LS, Schmitz HM, et al. Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells. Nat Immunol. 2014,15(5):473-81. doi: 10.1038/ni.2849
    Read this paper
  • Leyva-Castillo JM, Hener P, Michea P, et al. Skin thymic stromal lymphopoietin initiates Th2 responses through an orchestrated immune cascade. Nat Commun. 2013,4:2847. doi: 10.1038/ncomms3847
    Read this paper
  • Hong J, Yeom HJ, Lee E, et al. Islet allograft rejection in sensitized mice is refractory to control by combination therapy of immune-modulating agents. Transpl Immunol. 2013,28(2-3):86-92. doi: 10.1016/j.trim.2013.01.005
    Read this paper
  • Sanchez PJ, Kedl RM. An alternative signal 3: CD8⁺ T cell memory independent of IL-12 and type I IFN is dependent on CD27/OX40 signaling. Vaccine. 2012,30(6):1154-61. doi: 10.1016/j.vaccine.2011.12.017
    Read this paper
  • Kurche JS, Burchill MA, Sanchez PJ, et al. Comparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responses. J Immunol. 2010,185(4):2106-15. doi: 10.4049/jimmunol.1000172
    Read this paper
  • Vu MD, Clarkson MR, Yagita H, et al. Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol. 2006,176(3):1394-401.
    Read this paper